ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, phase 1 safety study to investigate the safety,
tolerability, seizure control, and quality of life in participants with medically-refractory
epilepsy who failed epilepsy surgery. These participants will have continued seizures despite
being at least 3 months post-epilepsy surgery (resective surgery with an intent to cure).